Nitya Ray - Actinium Pharmaceuticals Insider

Actinium Pharmaceuticals Inc -- USA Stock  

USD 0.40  0.04  11.11%

Executive Vice President Head - Product Development, Manufacturing and Supply Chain

Dr. Nitya G. Ray Ph.D. is Executive Vice President, Head Product Development, Manufacturing and Supply Chain of the company. Dr. Ray joins the Company from CytoDyn, Inc. where he was Sr. Vice President of Manufacturing and CMC Team Leader. At CytoDyn Dr. Ray developed robust and cost effective manufacturing processes for an antibody therapeutic drug candidate, currently in two Phase 3 clinical studies intended to treat and prevent HIV infection. Dr. Ray led a successful regulatory meetings with the FDA while simultaneously developing strategies for process development, scaleup, validation, commercial manufacturing, and supply chain to support potential commercialization of the CytoDyn HIV therapeutic drug candidate. Prior to CytoDyn, Dr. Ray spent 15 years at Progenics Pharmaceuticals, Inc. a radiopharmaceutical therapeutic and diagnostic company, most recently as Senior Vice President, Manufacturing. At Progenics, Dr. Ray led the development of scalable manufacturing processes and achieved orderofmagnitude cost reduction through improved productivity and scale. In addition, Dr. Ray built process and product development teams for Progenics small molecule, biologics, and radiopharmaceuticals that developed innovative processes for various phases of clinical development and commercial manufacturing. Dr. Ray supported inhouse cGMP biologics manufacturing for Phase 13 clinical development and managed relationships with Contract Development and manufacturing Organizations on a global basis. Dr. Ray also worked at HoffmanLa Roche with a focus on biopharmaceuticals and Verax Corporationrationration in roles of increasing responsibility
Age: 62  President Since 2017      
Ray has a Ph.D. in Biochemical Engineering and an M.S. in Chemical and Biochemical Engineering from Rutgers University and a B.S. in Chemical Engineering from Jadavpur University.

Nitya Ray Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (82.31) % which means that it has lost $82.31 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (167.94) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 5 records


Eyal BreitbartVascular Biogenics Ltd
Adam BuckleyVBI Vaccines Inc
Athena KartsaklisVBI Vaccines Inc
Erez FeigeVascular Biogenics Ltd
Yael CohenVascular Biogenics Ltd

Entity Summary

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York. Actinium Pharmaceuticals operates under Biotechnology classification in USA and traded on American Stock Exchange.Actinium Pharmaceuticals Inc (ATNM) is traded on American Stock Exchange in USA. It is located in NEW YORK, U.S.A and employs 23 people. Actinium Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Rebalancing Now

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Hide  View All  NextLaunch Portfolio Rebalancing
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Actinium Pharmaceuticals Inc to your portfolio

Top Management

Actinium Pharmaceuticals Leadership Team
Nitya Ray, President
Dale Ludwig, Executive, Ph.D
Sergio Traversa, Director, MBA
Dragan Cicic, COO, Ph.D
Steve OLoughlin, Executive
Kaushik Dave, CEO, MBA
Ajit Shetty, Director, MBA
Richard Steinhart, Director, MBA
Anil Kapur, Executive, MBA
David Nicholson, Director
Jehan Rowlands, President, Ph.D
C Nicholson, Director
Mark Berger, Executive
Steven Price, President
Sandesh Seth, Chairman, MBA

Stock Performance

Actinium Pharmaceuticals Performance Indicators